TY - JOUR
T1 - Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea
AU - Dy, Sydney M.
AU - Lorenz, Karl A.
AU - Naeim, Arash
AU - Sanati, Homayoon
AU - Walling, Anne
AU - Asch, Steven M.
PY - 2008
Y1 - 2008
N2 - Purpose: The experience of patients with cancer often involves symptoms of fatigue, anorexia, depression, and dyspnea. Methods: We developed a set of standards through an iterative process of structured literature review and development and refinement of topic areas and standards and subjected recommendations to rating by a multidisciplinary expert panel. Results: For fatigue, providers should screen patients at the initial visit, for newly identified advanced cancer, and at chemotherapy visits; assess for depression and insomnia in newly identified fatigue; and follow up after treatment for fatigue or a secondary cause. For anorexia, providers should screen at the initial visit for cancer affecting the oropharynx or gastrointestinal tract or advanced cancer, evaluate for associated symptoms, treat underlying causes, provide nutritional counseling for patients undergoing treatment that may affect nutritional intake, and follow up patients given appetite stimulants. For depression, providers should screen newly diagnosed patients, those started on chemotherapy or radiotherapy, those with newly identified advanced disease, and those expressing a desire for hastened death; document a treatment plan in diagnosed patients; and follow up response after treatment. For general dyspnea, providers should evaluate for causes of new or worsening dyspnea, treat or symptomatically manage underlying causes, follow up to evaluate treatment effectiveness, and offer opioids in advanced cancer when other treatments are unsuccessful. For dyspnea and malignant pleural effusions, providers should offer thoracentesis, follow up after thoracentesis, and offer pleurodesis or a drainage procedure for patients with reaccumulation and dyspnea. Conclusion: These standards provide a framework for evidence-based screening, assessment, treatment, and follow-up for cancer-associated symptoms.
AB - Purpose: The experience of patients with cancer often involves symptoms of fatigue, anorexia, depression, and dyspnea. Methods: We developed a set of standards through an iterative process of structured literature review and development and refinement of topic areas and standards and subjected recommendations to rating by a multidisciplinary expert panel. Results: For fatigue, providers should screen patients at the initial visit, for newly identified advanced cancer, and at chemotherapy visits; assess for depression and insomnia in newly identified fatigue; and follow up after treatment for fatigue or a secondary cause. For anorexia, providers should screen at the initial visit for cancer affecting the oropharynx or gastrointestinal tract or advanced cancer, evaluate for associated symptoms, treat underlying causes, provide nutritional counseling for patients undergoing treatment that may affect nutritional intake, and follow up patients given appetite stimulants. For depression, providers should screen newly diagnosed patients, those started on chemotherapy or radiotherapy, those with newly identified advanced disease, and those expressing a desire for hastened death; document a treatment plan in diagnosed patients; and follow up response after treatment. For general dyspnea, providers should evaluate for causes of new or worsening dyspnea, treat or symptomatically manage underlying causes, follow up to evaluate treatment effectiveness, and offer opioids in advanced cancer when other treatments are unsuccessful. For dyspnea and malignant pleural effusions, providers should offer thoracentesis, follow up after thoracentesis, and offer pleurodesis or a drainage procedure for patients with reaccumulation and dyspnea. Conclusion: These standards provide a framework for evidence-based screening, assessment, treatment, and follow-up for cancer-associated symptoms.
UR - http://www.scopus.com/inward/record.url?scp=51349102669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51349102669&partnerID=8YFLogxK
U2 - 10.1200/JCO.2007.15.9525
DO - 10.1200/JCO.2007.15.9525
M3 - Review article
C2 - 18688057
AN - SCOPUS:51349102669
SN - 0732-183X
VL - 26
SP - 3886
EP - 3895
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 23
ER -